What Current Studies Reveal About Reglan and Tardive Dyskinesia
Latest update (2025-07)
- FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]
Understanding the Legacy of General Health Education and Medication Risks
If you or a loved one takes Reglan (metoclopramide) for stomach issues, you may have heard about the risk of tardive dyskinesia—a condition causing involuntary movements. Current research continues to refine our understanding of how long-term use increases this risk. Building on decades of clinical observation, this page summarizes what recent studies report about who is most vulnerable and what follow-up care is recommended.
Reglan and Tardive Dyskinesia: A Critical Medical Concern
Reglan (metoclopramide) is a medication approved for short-term treatment of symptomatic gastroesophageal reflux and relief of symptoms in adults with diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The drug carries a boxed warning stating that metoclopramide can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). TD is characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities, and may be disfiguring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with longer duration of treatment and higher total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The approved indications limit use to 4 to 12 weeks for gastroesophageal reflux and advise avoiding treatment longer than 12 weeks for diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these limits, many patients have been prescribed Reglan for extended periods, increasing their exposure to the drug and the associated risk of TD. The label explicitly states that Reglan may suppress or partially suppress signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This masking effect complicates early detection and intervention.
Statute of Limitations for Reglan Claims in California
For patients in California who have developed TD after using Reglan, the statute of limitations is a critical legal consideration. California law generally requires that a personal injury lawsuit be filed within two years from the date of injury or from the date the injury was discovered, or reasonably should have been discovered. For TD, the timeline between exposure and documented harm can be variable. TD may develop months or years after starting Reglan, and symptoms may be subtle initially. The label warns that TD can be potentially irreversible, and immediate discontinuation is recommended if signs or symptoms appear (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, because TD can be masked by the drug itself, patients may not recognize the condition until after stopping Reglan, when symptoms become more apparent. Settlement-related considerations for affected patients include the adequacy of warnings provided by manufacturers. The boxed warning clearly states the risk of TD and the need for short-term use, but questions may arise about whether prescribers and patients were adequately informed about the specific risks, especially for off-label or long-term use. The label also advises against concomitant use of other drugs known to cause TD and recommends avoiding use in patients with Parkinson's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If a patient was not warned about these risks, or if the drug was prescribed for longer than recommended, this could be relevant in settlement negotiations.
Mechanism of Action and Risk Factors
The mechanistic pathway linking Reglan to TD involves dopamine receptor blockade in the basal ganglia, which can lead to supersensitivity and abnormal involuntary movements. The label notes that metoclopramide can cause extrapyramidal symptoms and neuroleptic malignant syndrome (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This pharmacological action is similar to that of antipsychotics, which are also associated with TD. For patients considering legal action, it is important to document the duration of Reglan use, total cumulative dosage, and the onset of TD symptoms. Medical records should include diagnoses of TD and any attempts to discontinue the drug. The statute of limitations clock may start when the patient first noticed symptoms or when a physician diagnosed TD. Given the potential for delayed recognition, patients should consult with an attorney experienced in pharmaceutical litigation to assess their specific timeline.
Summary and Next Steps
In summary, Reglan carries a known risk of causing TD, with the risk increasing with longer use. California's statute of limitations for such claims is typically two years from discovery of the injury. Patients who developed TD after using Reglan should seek legal advice promptly to preserve their rights. The adequacy of warnings and the duration of exposure are key factors in settlement considerations.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for Reglan-related tardive dyskinesia claims in California?
In California, the statute of limitations for personal injury claims, including those related to Reglan and tardive dyskinesia, is generally two years from the date of injury or from the date the injury was discovered, or reasonably should have been discovered. Because TD symptoms may develop gradually and can be masked by the drug, the clock may start when a patient first notices symptoms or receives a diagnosis. It is crucial to consult with an attorney promptly to evaluate your specific timeline.
Can I still file a claim if my TD symptoms appeared years after stopping Reglan?
Yes, it may still be possible to file a claim if the symptoms were not discovered until later. The discovery rule in California allows the statute of limitations to begin when the injury is discovered or should have been discovered. However, you should seek legal advice as soon as possible to ensure your claim is within the applicable time frame.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.